38MO IND.236: A Canadian Cancer Trial Group (CCTG) phase Ib trial of combined CFI-402257 and weekly paclitaxel (Px) in patients with HER2-negative (HER2-) advanced breast cancer (BC)
- Resource Type
- Source
- Annals of Oncology. 32:S16
- Subject
Oncology medicine.medical_specialty business.industry Advanced breast HER2 negative Weekly paclitaxel Cancer Hematology medicine.disease Internal medicine medicine In patient business - Language
- ISSN
- 0923-7534